Capstone Investment Advisors LLC Takes Position in Revolution Medicines, Inc. $RVMD

Capstone Investment Advisors LLC bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,200 shares of the company’s stock, valued at approximately $1,348,000.

A number of other institutional investors have also modified their holdings of the business. Contravisory Investment Management Inc. purchased a new stake in Revolution Medicines in the 2nd quarter valued at $32,000. Global Retirement Partners LLC grew its position in Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares during the last quarter. Torren Management LLC purchased a new position in Revolution Medicines during the 4th quarter worth $33,000. Johnson Financial Group Inc. acquired a new position in Revolution Medicines in the second quarter valued at $37,000. Finally, Arax Advisory Partners acquired a new position in Revolution Medicines in the fourth quarter valued at $38,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC increased their target price on shares of Revolution Medicines from $236.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. HC Wainwright boosted their price target on Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday. Guggenheim upped their price objective on Revolution Medicines from $235.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Oppenheimer increased their price objective on Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Piper Sandler lifted their target price on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $193.28.

Insider Buying and Selling at Revolution Medicines

In related news, CFO Jack Anders sold 20,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the transaction, the chief financial officer owned 123,269 shares of the company’s stock, valued at $20,749,870.77. This represents a 13.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sushil Patel sold 5,580 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the transaction, the director directly owned 21,656 shares in the company, valued at $4,071,111.44. This represents a 20.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 212,497 shares of company stock worth $38,206,486. 7.60% of the stock is currently owned by company insiders.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Revolution Medicines Trading Up 2.7%

Shares of Revolution Medicines stock opened at $221.15 on Friday. Revolution Medicines, Inc. has a 52-week low of $37.56 and a 52-week high of $224.31. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The company’s 50-day simple moving average is $192.43 and its 200-day simple moving average is $148.17. The firm has a market cap of $47.40 billion, a price-to-earnings ratio of -25.07 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the business posted ($1.31) EPS. As a group, equities research analysts anticipate that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.